Figure 4 | Scientific Reports

Figure 4

From: HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

Figure 4

Progression-free survival in NCT02564900 (DS8201-A-J101) using the two best-ranked human epidermal growth factor receptor 2 (HER2) quantitative continuous scoring-based features. (A) Kaplan-Meier analysis with binary spatial proximity scores (bSPS), all patients. (B) Kaplan-Meier analysis with bSPS, HER2-negative subgroup. (C) Kaplan-Meier analysis with percentage of optical density (OD)-positive cells, all patients. (D) Kaplan-Meier analysis with percentage of OD-positive cells, HER2-negative subgroup.

Back to article page